TABLE 2.
Antimicrobial resistance of 52 representative Shenzhen ETEC isolates.
| Antimicrobial agent1 | Antimicrobial resistance rate (%) |
||||||
| L11 (n = 7) | L2/4 (n = 12) | L4 (n = 10) | L7 (n = 4) | L-N1 (n = 4) | Other2 (n = 15) | Total (n = 52) | |
| NAL | 71 | 92 | 60 | 75 | 50 | 67 | 71 |
| AMP | 86 | 100 | 40 | 75 | 25 | 67 | 69 |
| AMS | 29 | 100 | 20 | 25 | 0 | 47 | 46 |
| AZI | 14 | 100 | 20 | 25 | 0 | 27 | 38 |
| TET | 43 | 50 | 20 | 100 | 100 | 27 | 37 |
| CTX | 57 | 25 | 30 | 25 | 0 | 47 | 31 |
| SXT | 14 | 50 | 30 | 25 | 75 | 33 | 29 |
| STR | 43 | 25 | 0 | 25 | 50 | 20 | 19 |
| CIP | 0 | 0 | 10 | 0 | 0 | 7 | 4 |
| CAZ | 0 | 0 | 0 | 0 | 0 | 7 | 2 |
| ESBL | 57 | 8 | 30 | 25 | 0 | 47 | 31 |
| MDR | 43 | 100 | 30 | 50 | 75 | 33 | 54 |
1Only 10 of 17 antimicrobial agents with at least one resistant isolate were shown. 2Lineages with <3 isolates together were defined as others. NAL, nalidixic acid; AMP, ampicillin; TET, tetracycline; AMS, ampicillin/sulbactam; CTX, cefotaxime; SXT, trimethoprim/sulfamethoxazole; AZI, azithromycin; STR, streptomycin; CIP, ciprofloxacin; CAZ, ceftazidime. ESBL, extended-spectrum β-lactamase; MDR, multidrug-resistant, defined as resistant to ≥3 classes of antimicrobial agents.